Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 4/20 | 0.33 |
| ▸ | EHMT2 | Q96KQ7 | 2/20 | 0.33 |
| ▸ | SUV39H2 | Q9H5I1 | 2/20 | 0.32 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.32 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.32 |
| ▸ | DNMT3A | Q9Y6K1 | 1/20 | 0.31 |
| ▸ | NSD2 | O96028 | 1/20 | 0.30 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.30 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.30 |
| ▸ | CDK9 | P50750 | 1/20 | 0.30 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.30 |
| ▸ | CFD | P00746 | 2/20 | 0.30 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL35212558 | 0.90 | PARP1 (0.33) | PDE4BEHMT2TLR9USP30DNMT3A | |
| SCHEMBL35212051 | 0.89 | SUV39H2 (0.35) | PDE4BEHMT2SUV39H2TLR9DNMT3A | |
| SCHEMBL35211815 | 0.89 | SUV39H2 (0.35) | PDE4BEHMT2SUV39H2TLR9DNMT3A | |
| SCHEMBL35212625 | 0.89 | SUV39H2 (0.35) | PDE4BEHMT2SUV39H2TLR9NSD2 | |
| SCHEMBL35212050 | 0.89 | SUV39H2 (0.35) | PDE4BEHMT2SUV39H2TLR9DNMT3A | |
| SCHEMBL35212331 | 0.85 | USP30 (0.32) | USP30SCN9AMAP4K4 | |
| SCHEMBL34465221 | 0.85 | USP30 (0.32) | USP30SCN9AMAP4K4 | |
| SCHEMBL34465127 | 0.85 | USP30 (0.32) | USP30SCN9AMAP4K4 | |
| SCHEMBL35212552 | 0.84 | TLR9 (0.34) | PDE4BEHMT2SUV39H2TLR9DNMT3A | |
| SCHEMBL35211460 | 0.83 | SUV39H2 (0.36) | PDE4BEHMT2SUV39H2TLR9NSD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125383-A1 | INDAZOLE INHIBITORS OF CYCLIC GMP-AMP SYNTHASE AND USES THEREOF | VENTUS THERAPEUTICS U.S., INC. (US) | 2026-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260125383-A1 | INDAZOLE INHIBITORS OF CYCLIC GMP-AMP SYNTHASE AND USES THEREOF | CGAS, PRKG1, GMPS | PDE4B 62/4885EHMT2 4649/4885SUV39H2 4809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.